Drug intelligence / Profile preview

canna-lozenge

Development stage: Discontinued
Lead developer: Dogecoin Cash
Modality: Small Molecules
Administration: Oral

Overview

The canna-lozenge is a cannabis-derived oral formulation developed by Cannabis Sativa, Inc. (now Dogecoin Cash, Inc.) for the treatment of hypertension. The product is based on a patented technology intended to deliver cannabinoids in a lozenge format to manage high blood pressure. However, following a strategic rebranding in late 2024, the developer pivoted entirely into cryptocurrency and blockchain technology, leaving the canna-lozenge as a legacy intellectual property asset with no active clinical development pipeline reported.

Other names: cannabis-derived lozenge

Targets

PPAR (PPAR family)CNR1 (Cannabinoid receptor 1)MOR (Mu opioid receptor)5-HT (Serotonin receptors)GPR55 (G protein-coupled receptor 55)Glycine receptor

Beyond the preview

Go deeper on canna-lozenge.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on canna-lozenge.

Explore the full profile